2021 annual performance forecast: Chutian Technology, Dongfulong and other stocks are expected to increase

With the end of the year approaching, the 2021 annual performance forecast has also begun to surface
.
According to statistics, as of November 17, more than 30 companies have announced their 2021 annual performance forecasts, of which nearly 70% of the companies have reported good news.
The doubling stocks are mainly concentrated in the pharmaceutical and biological, transportation, and chemical industries
.
In the pharmaceutical equipment industry, although no listed pharmaceutical machinery company has disclosed its 2021 annual performance forecast, many institutions have already forecasted the performance of some listed pharmaceutical machinery companies in 2021.
Among them, Chutian Technology, Tofflon, etc.
The performance of individual stocks are all pre-increased
.
2021 Annual Performance Forecast: Chutian Technology, Tofflon and other individual stocks are expected to increase (Source: Pharmaceutical Network) Tofflon: Forecast net profit in 2021 will increase by 57.
23% year-on-year.
As of November 17, 2021, there will be a total of Essence within 6 months Eight institutions including Securities, Zheshang Securities, Guosheng Securities, CITIC Construction Investment, and China Sea Securities have made predictions on Tofflon’s 2021 results; Tofflon’s 2021 earnings per share are forecasted to be 1.
16 yuan, a year-on-year increase of 56.
76%; It is predicted that the net profit in 2021 will be 729 million yuan, a year-on-year increase of 57.
23%
.
In terms of recent institutional forecasts, on October 29, Essence Securities released a research report on "Three Quarterly Report Results Meet Expectations, Diversified Layout Continued Advancement", which believed that the diversified layout of Teflon’s products was effective, and domestic substitution was superimposed on overseas expansion.
Long-term development
.
It is estimated that the company’s revenue growth rates from 2021 to 2023 will be 43.
3%, 23.
2%, and 20.
9%, respectively, and net profit growth rates will be 64.
6%, 23.
8%, and 21.
2%, respectively.
The growth is outstanding, and the investment rating of Buy-A is given.
The 6-month target price is 48.
57 yuan, which is equivalent to a dynamic P/E ratio of 40 times in 2021
.
In the past 6 months, Essence Securities, Guosheng Securities, Essence Securities, Guosheng Securities, and Guohai Securities have given Tofflon a "buy" rating.
In addition, Tofflon has also received Zheshang Securities, Industrial Securities, and Industrial Securities.
Three securities institutions "increased their holdings
.
" According to data, Tofflon is a comprehensive pharmaceutical equipment service provider that provides global pharmaceutical companies with overall solutions for pharmaceutical processes, core equipment, and system engineering.

.
Chutian Technology: Forecast net profit in 2021 will increase by 145.
25% year-on-year.
Chutian Technology's net profit in the first three quarters exceeded 400 million yuan, which has reached twice the net profit for the whole year of 2020
.
According to the financial report, the main reason for the company's revenue growth in the first three quarters was a 98% increase in new orders over the same period in 2020
.
Insiders believe that Chutian Technology has sufficient orders in hand, which is a strong guarantee for the company to maintain high growth in the fourth quarter and subsequent quarters
.
As of November 17, 2021, within 6 months, five institutions including Guosen Securities, Southwest Securities, China Securities, Dongxing Securities, and Guohai Securities have made predictions on Chutian Technology’s 2021 annual results; forecasted 2021 earnings per share of 0.
87 Yuan, a year-on-year increase of 129.
55% over the previous year
.
Net profit for 2021 is predicted to be 492 million yuan, a year-on-year increase of 145.
25% .
In the past six months, Southwest Securities, Dongxing Securities, Southwest Securities, Guohai Securities, and Dongxing Securities have all given Chutian Technology a "buy" rating
.
Among them, Southwest Securities released comments on its third quarterly report for 2021 on October 24, stating that the downstream pharmaceutical industry is booming and the company's profitability continues to improve
.
At the same time, the company established Chutian Siyoute and Chutian Microspheres to deploy high-barrier biopharmaceutical consumables business
.
It is estimated that the company's net profit attributable to the parent will be 530 million yuan, 600 million yuan, and 770 million yuan from 2021 to 2023.
The EPS will be 0.
93 yuan, 1.
06 yuan, and 1.
36 yuan, respectively.
The corresponding valuations are 21 times, 19 times, and 15 times, respectively
.
Considering that the company is a leading domestic pharmaceutical equipment company, maintain the "Buy" rating
.
Since its establishment, Chutian Technology has been committed to providing professional and personalized pharmaceutical equipment solutions for pharmaceutical companies.
Its main business is the research and development, design, production, sales and service of pharmaceutical equipment
.
Tailin Bio: forecasts 2021 net profit to increase by 44.
67% year-on-year.
As of November 17, 2021, within 6 months, a total of one institution, China Securities Construction Investment, has made a prediction on Tailin Bio's 2021 annual performance; forecast 2021 net profit is 0.
70 Billion yuan, a year-on-year increase of 44.
67%
.
In addition, CITIC Construction Investment is rated as BUY
.
Public information shows that Tailin Bio's main business is the research and development, manufacturing and sales of pharmaceutical equipment such as microbial detection and control technology system products and organic matter analysis instruments
.